




Gated on FSC/SSC/LIVE cells

FIG. 1




FIG. 2




FIG. 3

Schematic of Truncated Cell Tags

WO 2018/226897

PCT/US2018/036357

4/20





FIG. 4A

Schematic of Chimeric Truncated Cell Tags




FIG. 4B

Schematic of Chimeric Truncated Cell Tags







FIG. 4C



Gated on FSC/SSC/LIVE/CD3+ cells
D163890 PBMCs

FIG. 4D



Gated on FSC/SSC/LIVE/CD3+ cells

FIG. 4E





FIG. 5A



Gated on FSC/SSC/LIVE/CD3+

FIG. 5B





FIG. 6



5:1 E:T ratio; normalized to EGFRt expressing cells

FIG. 7




FIG. 8






FIG. 9



First generation Truncated Cell Tags



Next generation Truncated Cell Tags




FIG. 10




FIG. 11




FIG. 12

Cetuximab mediated ADCC of CAR-T cells co-expressing HER1t





FIG. 13A

Cetuximab mediated ADCC of CAR-T cells co-expressing HER1t



E: Effector NK Cells
T: Target Cells Expressing Cell Tag
E:T Ratio= 1:1
C: Cetuximab at 0.1 µg/ml
R: Rituximab at 0.1 µg/ml

FIG. 13B




FIG. 14